What’s the difference between Ozempic and Victoza, and which is prescribed in Europe?

Ozempic vs Victoza explained: semaglutide vs liraglutide, GLP-1 receptor agonists, dosing frequency, weight effects, and prescribing criteria.

In this episode, we compare Ozempic (semaglutide) and Victoza (liraglutide) and how doctors decide between them under EU medical guidance.

You’ll learn:

• How both medications work (GLP-1 receptor agonists that improve glucose control)

• Key difference: once-weekly Ozempic vs once-daily Victoza

• Indications for type 2 diabetes and weight management criteria

• Differences in average HbA1c reduction and weight outcomes in trials

• Common side effects: nausea, vomiting, diarrhoea

• Monitoring requirements: kidney function, HbA1c, cardiovascular risk

• Red flag symptoms such as severe abdominal pain or persistent vomiting

• Situations where treatment choice depends on tolerance, dosing preference, or medical history

We explain how doctors assess HbA1c, BMI, weight-related conditions, cardiovascular profile, concurrent medications, and gastrointestinal tolerance during an online consultation in the EU. Selection depends on approved indications and individual risk assessment.

This episode reflects the clinical standards used by Mobi Doctor, where metabolic consultations are reviewed by a registered physician in line with EU prescribing guidance.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/ozempic-vs-victoza